TP53 and head and neck squamous cell carcinoma: Although its potential role as a prognostic and predictive biomarker has been debated [33, 34], as well as its use for diagnosing recurrent or minimal residual disease during follow-up after treatment [35–38], TP53 has, to our knowledge, not yet been proposed as a potential diagnostic biomarker for the early detection of locoregional metastases of HNSCC.